Tempest Therapeutics
Development-stage biotechnology company.
Launch date
Employees
Market cap
AUD56.5m
Enterprise valuation
AUD40m (Public information from Sep 2024)
Share price
$1.41 TPST
San Francisco California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | - | 10.7m |
| EBITDA | (19.0m) | (26.6m) | (34.1m) | (27.7m) | (35.5m) | (42.6m) | (50.8m) |
| % EBITDA margin | - | - | - | - | - | - | (474 %) |
| Profit | (19.2m) | (28.3m) | (35.7m) | (29.5m) | (36.6m) | (44.5m) | (58.6m) |
| % profit margin | - | - | - | - | - | - | (547 %) |
| EV / revenue | - | - | - | - | - | - | 3.0x |
| EV / EBITDA | - | -1.4x | -0.3x | -3.1x | -0.9x | -0.8x | -0.6x |
| R&D budget | 14.4m | 17.2m | 22.5m | 17.5m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $5.0m | Early VC | |
| N/A | N/A | IPO | |
$70.0m | Series B | ||
N/A | Merger | ||
$30.0m | Private Placement VC | ||
* | $15.0m | Post IPO Equity | |
| Total Funding | AUD162m | ||
Related Content
Recent News about Tempest Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
